Company Filing History:
Years Active: 2006-2010
Title: Innovations of Chih-Ping Liu in Antitumor and Antiviral Therapies
Introduction
Chih-Ping Liu is a prominent inventor based in San Francisco, CA, known for his significant contributions to the field of biotechnology. He holds a total of six patents, focusing on innovative therapies that combine antitumor and antiviral agents with low-toxicity, long-circulating human interferon-alpha analogs. His work aims to enhance treatment efficacy while minimizing side effects.
Latest Patents
Liu's latest patents include groundbreaking developments in antitumor and antiviral combination therapies. One notable patent describes interferon-alpha (IFNα) analog proteins modified by the chemical attachment of hydrophilic polymer moieties, such as polyethylene glycol chains. These modifications allow for the use of IFNα analog proteins in combination therapies with antiviral and/or antitumor agents. The patent outlines that the IFNα analog protein has an amino acid sequence differing from native human IFNα by one or more residues in the N-terminal region, specifically between residues 1-27. Another patent focuses on low-toxicity, long-circulating human interferon-alpha PEGylated mutants, which are also designed to treat viral diseases and other disorders.
Career Highlights
Chih-Ping Liu has made significant strides in his career, particularly through his work at Pepgen Corporation. His innovative approaches to modifying interferon-alpha proteins have positioned him as a key figure in the development of new therapeutic strategies. His research has the potential to transform treatment protocols for various viral and cancerous conditions.
Collaborations
Liu collaborates with talented professionals in his field, including Lorelie H Villarete and Yoshihiro Sokawa. These collaborations enhance the research and development of effective therapies, contributing to the advancement of medical science.
Conclusion
Chih-Ping Liu's contributions to biotechnology through his innovative patents and collaborative efforts highlight his commitment to improving healthcare outcomes. His work in developing low-toxicity therapies represents a significant advancement in the treatment of viral diseases and cancer.